Eisai Co., Ltd. is confident that it has the necessary data to convince the US Centers for Medicare and Medicaid Services to grant broader coverage for its Biogen, Inc.-partnered Alzheimer’s drug candidate lecanemab, if the US Food and Drug Administration approves it next month – setting it up for a potentially much better commercial outlook than the firms’ Aduhelm faced.
Many in the Alzheimer's field, impressed with the quality and amount of data presented from the Phase III Clarity AD...







